Details for Patent: 9,149,477

Title:	5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract:	Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below: ##STR00001##
Inventor(s):	Kesicki; Edward A. (Bothell, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA)
Assignee:	ICOS Corporation (Indianapolis, IN)
Filing Date:	May 21, 2014
Application Number:	14/284,331
Claims:	1. A method of inhibiting phosphatidylinositol 3-kinase activity in a cell with a compound ##STR00184## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, further comprising administering the compound or a pharmaceutically acceptable salt thereof to an individual in need thereof. 3. The method of claim 2, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 4. The method of claim 2, wherein the compound is ##STR00185## 5. The method of claim 4, wherein the compound is the S-enantiomer. 6. The method of claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein the compound is ##STR00186## 8. The method of claim 7, wherein the compound is the S-enantiomer. 9. A method of inhibiting phosphatidylinositol 3-kinase delta activity in a cell, comprising administering to an individual in need thereof the compound ##STR00187## or a pharmaceutically acceptable salt thereof. 10. The method of claim 9, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 11. The method of claim 9, wherein the compound is ##STR00188## 12. The method of claim 11, wherein the compound is the S-enantiomer.